ESR1 and breast carcinoma: In vitro studies conducted in ER+ breast cancer cell models by our laboratory [11,13,14] and others [15,16] showed that the combination of an antiestrogen plus an antiprogestin induced significantly higher levels of cytostasis and cytotoxicity (cell death) than did treatment with the antiestrogen or antiprogestin used as a single agent.